This discussion focuses on strategies to manage neutropenia associated with SG, including the use of prophylactic growth factors and timing of their administration, comparing management approaches between clinicians.
Video Player is loading.
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Remaining Time -0:00
1x
2x
1.75x
1.5x
1.25x
1x, selected
0.75x
0.5x
Chapters
descriptions off, selected
captions settings, opens captions settings dialog
captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
Please comment on your management strategy to mitigate neutropenia associated with SG.
What patient characteristics do you consider when deciding to utilize prophylactic growth factor support vs. utilize GCSF as secondary prophylaxis in your clinical practice?
What days do you typically administer either pegylated growth factors and/or daily filgrastim?
Please comment on your management strategy to mitigate neutropenia (any similarities vs. differences)